- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04246047
Utvärdering av effekt och säkerhet av Belantamab Mafodotin, Bortezomib och Dexametason kontra Daratumumab, Bortezomib och Dexametason hos deltagare med återfall/refraktärt multipelt myelom (DREAMM 7)
DRÖM 7: En multicenter, öppen etikett, randomiserad fas III-studie för att utvärdera effektiviteten och säkerheten av kombinationen av Belantamab Mafodotin, Bortezomib och Dexametason (B-Vd) jämfört med kombinationen av Daratumumab, Bortezomib och Dexametason (D-Vdadason) ) hos deltagare med återfall/refraktärt multipelt myelom
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Utökad åtkomst
Kontakter och platser
Studieorter
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- GSK Investigational Site
-
Liverpool, New South Wales, Australien, 2170
- GSK Investigational Site
-
Newcastle, New South Wales, Australien, 2298
- GSK Investigational Site
-
St Leonards, New South Wales, Australien, 2065
- GSK Investigational Site
-
Wollongong, New South Wales, Australien, 2500
- GSK Investigational Site
-
-
Queensland
-
Benowa, Queensland, Australien, 4217
- GSK Investigational Site
-
Herston, Queensland, Australien, 4029
- GSK Investigational Site
-
-
South Australia
-
Ashford, South Australia, Australien, 5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- GSK Investigational Site
-
Heidelberg, Victoria, Australien, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Australien, 3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch, Western Australia, Australien, 6150
- GSK Investigational Site
-
Nedlands, Western Australia, Australien, 6009
- GSK Investigational Site
-
-
-
-
-
Roeselare, Belgien, 8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgien, 1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert, Brussels Capital, Belgien, 1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgien, 9000
- GSK Investigational Site
-
-
-
-
-
Joinville, Brasilien, 89201-260
- GSK Investigational Site
-
Natal, Brasilien, 59075-740
- GSK Investigational Site
-
Rio de Janeiro, Brasilien, 22775001
- GSK Investigational Site
-
São Paulo, Brasilien, 04537-080
- GSK Investigational Site
-
São Paulo, Brasilien, 05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasilien, 88020-210
- GSK Investigational Site
-
-
-
-
-
Amiens, Frankrike, 80054
- GSK Investigational Site
-
Caen, Frankrike, 14033
- GSK Investigational Site
-
Nice, Frankrike, 06200
- GSK Investigational Site
-
Paris, Frankrike, 75651
- GSK Investigational Site
-
Rennes, Frankrike, 35033
- GSK Investigational Site
-
-
-
-
Arizona
-
Yuma, Arizona, Förenta staterna, 85364
- GSK Investigational Site
-
-
Kansas
-
Mission, Kansas, Förenta staterna, 66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver, North Carolina, Förenta staterna, 80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash, Ohio, Förenta staterna, 45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler, Texas, Förenta staterna, 75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke, Virginia, Förenta staterna, 24014
- GSK Investigational Site
-
-
-
-
-
Athens, Grekland, 11528
- GSK Investigational Site
-
Thessaloniki, Grekland, 54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli, East Macedonia and Thrace, Grekland, 681 00
- GSK Investigational Site
-
-
-
-
-
Jerusalem, Israel, 91120
- GSK Investigational Site
-
Kfar Saba, Israel, 44281
- GSK Investigational Site
-
Ramat Gan, Israel, 52621
- GSK Investigational Site
-
Tel Aviv, Israel, 64239
- GSK Investigational Site
-
-
-
-
-
Bergamo, Italien, 24127
- GSK Investigational Site
-
Bologna, Italien, 40138
- GSK Investigational Site
-
Brescia, Italien, 25123
- GSK Investigational Site
-
Catania, Italien, 95123
- GSK Investigational Site
-
Meldola FC, Italien, 47014
- GSK Investigational Site
-
Milan, Italien, 20133
- GSK Investigational Site
-
Ravenna, Italien, 48121
- GSK Investigational Site
-
Roma, Italien, 00168
- GSK Investigational Site
-
Siena, Italien, 53100
- GSK Investigational Site
-
Torino, Italien, 10126
- GSK Investigational Site
-
-
-
-
-
Aichi, Japan, 467-8602
- GSK Investigational Site
-
Aichi, Japan, 441-8570
- GSK Investigational Site
-
Aomori, Japan, 030-8553
- GSK Investigational Site
-
Ehime, Japan, 790-8524
- GSK Investigational Site
-
Fukuoka, Japan, 806-8501
- GSK Investigational Site
-
Fukuoka, Japan, 807-8555
- GSK Investigational Site
-
Fukuoka, Japan, 810-8563
- GSK Investigational Site
-
Fukuoka, Japan, 815-8555
- GSK Investigational Site
-
Gifu, Japan, 503-8502
- GSK Investigational Site
-
Gunma, Japan, 377-0280
- GSK Investigational Site
-
Hyōgo, Japan, 670-8540
- GSK Investigational Site
-
Kanagawa, Japan, 247-8533
- GSK Investigational Site
-
Kanagawa, Japan, 221-0855
- GSK Investigational Site
-
Kochi, Japan, 781-8555
- GSK Investigational Site
-
Nagano, Japan, 392-8510
- GSK Investigational Site
-
Okayama, Japan, 701-1192
- GSK Investigational Site
-
Osaka, Japan, 545-8586
- GSK Investigational Site
-
Osaka, Japan, 530-0012
- GSK Investigational Site
-
Shizuoka, Japan, 411-8777
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Beijing, Kina, 100191
- GSK Investigational Site
-
Beijing, Kina, 100020
- GSK Investigational Site
-
Changchun, Kina, 130012
- GSK Investigational Site
-
Guangzhou, Kina, 510060
- GSK Investigational Site
-
Guangzhou, Kina, 510515
- GSK Investigational Site
-
Hangzhou, Kina, 310003
- GSK Investigational Site
-
Jinan, Kina, 250012
- GSK Investigational Site
-
Nanjing, Kina, 210008
- GSK Investigational Site
-
Shenyang, Kina, 110001
- GSK Investigational Site
-
Suzhou, Kina, 215006
- GSK Investigational Site
-
Tianjin, Kina, 300020
- GSK Investigational Site
-
Zhengzhou, Kina, 450052
- GSK Investigational Site
-
-
-
-
-
Groningen, Nederländerna, 9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht, South Holland, Nederländerna, 3318 AT
- GSK Investigational Site
-
-
-
-
-
Christchurch, Nya Zeeland, 8011
- GSK Investigational Site
-
Dunedin, Nya Zeeland, 9054
- GSK Investigational Site
-
Takapuna Auckland, Nya Zeeland, 1309
- GSK Investigational Site
-
Wellington, Nya Zeeland, 6021
- GSK Investigational Site
-
-
-
-
-
Chorzów, Polen, 41-500
- GSK Investigational Site
-
Krakow, Polen, 30510
- GSK Investigational Site
-
Lodz, Polen, 93-513
- GSK Investigational Site
-
Lublin, Polen, 20-081
- GSK Investigational Site
-
Lublin, Polen, 20-090
- GSK Investigational Site
-
Nowy Sącz, Polen, 33-300
- GSK Investigational Site
-
Poznan, Polen, 60-569
- GSK Investigational Site
-
Warsaw, Polen, 02-781
- GSK Investigational Site
-
-
-
-
-
Moscow, Ryssland, 125284
- GSK Investigational Site
-
Nizhny Novgorod, Ryssland, 603126
- GSK Investigational Site
-
Novosibirsk, Ryssland, 630087
- GSK Investigational Site
-
Saint Petersburg, Ryssland, 191024
- GSK Investigational Site
-
Saint Petersburg, Ryssland, 197 089
- GSK Investigational Site
-
Samara, Ryssland, 443021
- GSK Investigational Site
-
Saratov, Ryssland, 410028
- GSK Investigational Site
-
Ufa, Ryssland, 450083
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Barcelona, Spanien, 08916
- GSK Investigational Site
-
Cáceres, Spanien, 10003
- GSK Investigational Site
-
Gijón, Spanien, 33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega, Spanien, 08908
- GSK Investigational Site
-
MOstoles Madrid, Spanien, 28933
- GSK Investigational Site
-
Madrid, Spanien, 28007
- GSK Investigational Site
-
Madrid, Spanien, 31008
- GSK Investigational Site
-
Murcia, Spanien, 30008
- GSK Investigational Site
-
PamplonaNavarra, Spanien, 31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Spanien, 28223
- GSK Investigational Site
-
Salamanca, Spanien, 37007
- GSK Investigational Site
-
-
-
-
-
Bournemouth, Storbritannien, BH7 7DW
- GSK Investigational Site
-
Cardiff, Storbritannien, CF14 4XW
- GSK Investigational Site
-
Dundee, Storbritannien, DD1 9SY
- GSK Investigational Site
-
Leicester, Storbritannien, LE1 5WW
- GSK Investigational Site
-
London, Storbritannien, W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent, Storbritannien, ST4 6QG
- GSK Investigational Site
-
Sutton, Storbritannien, SM2 5PT
- GSK Investigational Site
-
-
-
-
-
Pusan, Sydkorea, 49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, Sydkorea, 13620
- GSK Investigational Site
-
Seoul, Sydkorea, 06351
- GSK Investigational Site
-
Seoul, Sydkorea, 06591
- GSK Investigational Site
-
Ulsan, Sydkorea, 44033
- GSK Investigational Site
-
-
-
-
-
Brno, Tjeckien, 625 00
- GSK Investigational Site
-
Hradec Králové, Tjeckien, 500 05
- GSK Investigational Site
-
Ostrava, Tjeckien, 708 52
- GSK Investigational Site
-
Prague, Tjeckien, 128 08
- GSK Investigational Site
-
-
-
-
-
Cologne, Tyskland, 50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Tyskland, 89081
- GSK Investigational Site
-
-
Bavaria
-
München, Bavaria, Tyskland, 81377
- GSK Investigational Site
-
Würzburg, Bavaria, Tyskland, 97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Tyskland, 40225
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- GSK Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Belantamab mafodotin och Bortezomib plus dexametason (arm A)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
Aktiv komparator: Daratumumab och Bortezomib plus dexametason (arm B)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsram: Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Antal deltagare med onormala ögonfynd vid oftalmisk undersökning
Tidsram: Upp till 73 månader
|
Upp till 73 månader
|
|
|
Complete Response Rate (CRR)
Tidsram: Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
Tidsram: Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
Tidsram: Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
Tidsram: Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
Tidsram: Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
Tidsram: Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
Tidsram: Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Tidsram: Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
Tidsram: Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
Tidsram: Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
Tidsram: Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Tidsram: Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
Tidsram: Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Tidsram: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Tidsram: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Tidsram: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Tidsram: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
Tidsram: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Tidsram: Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Tidsram: Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
Tidsram: Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: GSK Clinical Trials, GlaxoSmithKline
Publikationer och användbara länkar
Allmänna publikationer
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Neoplasmer
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Neoplasmer, Plasmacell
- Hemostatiska störningar
- Paraproteinemier
- Blodproteinstörningar
- Hemorragiska störningar
- Hemiska och lymfsjukdomar
- Multipelt myelom
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Polycykliska föreningar
- Oorganiska kemikalier
- Graviditet
- Graviditet
- Steroider
- Fusion-ringföreningar
- Steroider, fluorerade
- Graviditet
- Borrsyror
- Syror, icke -karboxyl
- Syror
- Boreföreningar
- Pyraziner
- Bortezomib
- Dexametason
- daratumumab
- belantamab mafodotin
Andra studie-ID-nummer
- 207503
- 2018 (U.S.S. NIH-anslag/kontrakt)
- 2018-003993-29 (Registeridentifierare: EudraCT (EU))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .